Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $6 million versus the consensus estimate of $4.7 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.